Background
==========

Hepatocellular carcinoma (HCC) is a common frequent human malignancy and contributes significantly to worldwide cancer-related morbidity and mortality \[[@b1-anntransplant-25-e919414]\]. Moreover, the incidence of HCC in Asia and Western countries, including the USA, has grown markedly in recent years, and, according to estimates, it will continuously rise in the next 2 decades \[[@b1-anntransplant-25-e919414]\]. In cases of unresectable HCC, LTX is a standard therapeutic modality that offers a realistic chance of healing. Many HCC transplant candidates receive a bridging therapy -- transarterial chemoembolization (TACE) -- prior to LTX \[[@b2-anntransplant-25-e919414]\].

Chronic hepatic inflammation and autoimmune disorders that progress to liver cirrhosis are key mediators in hepatocarcinogenesis \[[@b3-anntransplant-25-e919414]\]. However, the mechanisms by which chronic inflammation influences this process are not well understood. Furthermore, it is unclear to what extent these tumor infiltrates of immune-competent cells in the recipient liver prior to LTX affect disease outcome after transplantation.

Tumor-associated macrophages (TAMs) are essential mediators of inflammation in the vicinity of cancer \[[@b4-anntransplant-25-e919414]\]. They contribute to tumor progression by deploying many different mechanisms comprising genetic instability, nurturing cancer stem cells, enhancing the process of metastasis, and reducing the potency of the protective adaptive immunity \[[@b5-anntransplant-25-e919414]\]. Depending on the established macrophage polarization state (M1 or M2 functional mode) in the tumor microenvironment, TAMs can profoundly influence the effectiveness of cytoreductive chemotherapies, either by antagonizing immunologic anti-tumor activity or contributing to the antineoplastic efficacy \[[@b6-anntransplant-25-e919414]\]. Furthermore, monocyte/macrophage functions in the tumor microenvironment have been mechanistically linked to the formation of tumor necrosis \[[@b7-anntransplant-25-e919414]\]. The occurrence of treatment-induced histologic necrosis in cancerous tissues after neoadjuvant therapies has also been associated with tumor recurrence and patient outcomes \[[@b8-anntransplant-25-e919414]\].

Neoangiogenesis in the highly vascularized tumor microenvironment of HCC is an established modulator of hepatocarcinogenesis and is an attractive opportunity for anticancer therapy \[[@b9-anntransplant-25-e919414]\]. In this setting, the TIE2-angiopoietin system exerts a significant impact on tumor progression and has been recognized as an essential anti-angiogenic pathway for future drug development \[[@b10-anntransplant-25-e919414]\]. Angiopoietins, especially angiopoietin-1 and -2, have recently been shown to be expressed in tumorous tissues, such as hepatocellular carcinoma \[[@b11-anntransplant-25-e919414]\]. The angiopoietin family comprises several factors of angiogenesis that interact with the TIE2 receptor and regulate the pathological and physiological angiogenic processes \[[@b12-anntransplant-25-e919414]\]. CD14^+^ non-classical monocytes expressing the functional angiopoietin TIE2 receptor contribute significantly to neovascularization processes in solid tumors, utilizing paracrine mechanisms in the vicinity of tumorous neo-vessels \[[@b12-anntransplant-25-e919414]\]. These TIE-expressing monocytes (TEMs) are M2 phenotyped and are responsible for most of the angiogenic activity in the tumor microenvironment \[[@b13-anntransplant-25-e919414]\].

The immunologic competence of the recipient is profoundly altered after solid organ transplantation. In this setting, the clinical significance of recipient-related factors of angiogenesis, related tumor infiltrating monocytes/macrophages, and formation of necrosis in the tumor microenvironment concerning tumor progression is unknown. Thus, based on previous results on the importance of the immune system in hepatobiliary cancer, we hypothesized that, in the recipient's native tumor microenvironment prior transplantation, a coherent construct composed of infiltrating monocytes/macrophages, related necrosis, and factors of angiogenesis exert a significant effect on clinical outcome after LTX. In the present study, we demonstrate that, in the microenvironment of HCC, the tissue densities of the above-mentioned biomarkers are strongly associated. Furthermore, we showed that they have a substantial influence on graft rejection, incidence of metastatic disease, and survival of patients after transplantation.

Material and Methods
====================

Patients and tumor samples
--------------------------

The Institutional Ethics Commission approved this retrospective study (no. 234-14-14072014). Our study included 88 liver transplant recipients with HCC arising *de novo* in cirrhotic livers. The study period began on 10 April 2002 and ended on 10 April 2015. Inclusion criteria comprised patients with histologically confirmed HCC with no chemotherapy or radiation prior surgery who received LTX. No pediatric patients were included and none of the patients received antiangiogenic treatment modalities (e.g., sorafenib or prior LTX). LTX patients who received re-transplant in the further course or who died within 90 days after the surgery were excluded from the study. The median waiting time for LTX was 5.05 months for patients who received bridging therapy to LTX with TACE and 5.4 months for patients without TACE. Patients with 'high urgency' status had a median waiting time for LTX of 2 days. The clinical background, underlying liver disease, and demographics of the patients are summarized in [Table 1](#t1-anntransplant-25-e919414){ref-type="table"}. [Figure 1](#f1-anntransplant-25-e919414){ref-type="fig"} depicts a flowchart describing the patient selection process for our study.

Some of the HCC patients had a history of viral hepatitis (HBV or HCV). Antiviral therapy of the liver transplant recipients varied in respect to the type of viral hepatitis (HBV or HCV). Before LTX, patients with HBV received the nucleoside analogs lamivudine, entecavir, or tenofovir. Intraoperatively, 10 000 IE of hepatitis B immune globulins was administered. After LTX, the preoperatively initiated nucleoside analogs were maintained. Post-transplant monitoring of the anti-HBs titer and passive immunization, if \<100 IE/L, were performed on a regular basis. Standard treatment of HCV transplant candidates before LTX consisted of PEGylated interferon (peg-IFN)-α and ribavirin. This regimen was maintained after the LTX. In some cases, peptidomimetic inhibitors (telaprevir) or protease inhibitors (boceprevir) were added.

Standard immunosuppressive regimens were administered after transplantation. All patients were initially given the calcineurin inhibitor tacrolimus. In 66/88 (75.0%) cases, the protocols also included the mTOR inhibitor everolimus. Due to adverse effects, in 16/88 (18.2%) cases tacrolimus was replaced by cyclosporine in the subsequent course. The standard protocols in all patients also included prednisolone in the initial phase after transplantation. This was tapered off and stopped 8 weeks after surgery. In some patients, mycophenolate mofetil was also given, but was stopped as soon as possible in the subsequent course.

Our study population comprised 2 cohorts: patients without (n=33) and patients with neoadjuvant TACE (n=55) prior to LTX. TACE in our institution was performed to sustain tumor control while bridging to transplantation. TACE procedures were performed using a standard protocol consisting of doxorubicin, mitomycin C, and lipiodol. In local anesthesia, angiography of the hepatic artery and subsequent selective visualization of tumor vessels was performed. In the next step, doxorubicin, mitomycin C, and lipiodol were selectively applied to the tumor vessels. In the control angiography and CT scan of the abdomen, depot of lipiodol with reduced and embolized vessels in the vicinity of the tumor were documented. TACE using drug-eluting beads (DEB) was performed in none of the cases.

Graft rejection was defined as rejection verified by histology after percutaneous liver biopsy using Banff criteria, or suspected rejection with improvement of liver function and enzymes after methylprednisolone i.v. therapy for at least 72 h. In all patients, hepatectomy and LTX were performed with curative intent. Paraffin-embedded, formalin-fixed tumor samples with a representative HCC specimen were retrieved from the Institute of Pathology. Experienced researchers (KD and GA) in histopathology carried out the histological and immunohistological analyses. An independent pathologist (KS) supervised the assessment process. The evaluation was carried out without knowledge of the outcome of the patients or the corresponding patient characteristics.

Immunohistology and tumor tissue densities analysis of angiopoietins and cellular immunologic infiltrates
---------------------------------------------------------------------------------------------------------

The protocols for immunohistology, scoring of immune cells, and patient assignment to different groups for statistical assessment were carried out as previously described \[[@b14-anntransplant-25-e919414]--[@b16-anntransplant-25-e919414]\]. Briefly, we evaluated the tumor slice thoroughly for positive antibody staining, whereby the tumor infiltrating front (TIF) and the tumor central area (TCA) were examined separately. Positive staining for cellular infiltrates and angiopoietins seen in up to 5% of the tumor tissue was designated as negative/absent (0--5% positive cells, score 0), whereas \>5% was designated as positive/present (\>5% positive cells, score 1). Then, we grouped the patients by the presence or absence of the various immunologic entities and angiopoietins ([Table 1](#t1-anntransplant-25-e919414){ref-type="table"}).

Occurrence of histologic tumor necrosis
---------------------------------------

The appearance of tumor necrosis in HCC tissues was categorized into 1 for negative or 2 for positive, and then the liver transplants were assigned to a Necrosis^+^ or Necrosis^−^ group, according to their 'positive' or 'negative' necrosis scores \[[@b17-anntransplant-25-e919414],[@b18-anntransplant-25-e919414]\].

Statistical analysis
--------------------

We used SPSS statistical software to conduct the univariate and survival analysis. A chi-squared test (χ^2^ test) was used to determine whether there was a significant difference between the observed frequencies in the categorical variables (clinicopathologic characteristics) in our study. Patient survival was analyzed with the log-rank test. Significant values from the univariate analysis and the ones that demonstrated an outlined trend towards significance were further processed in a Cox regression analysis model in a step-wise manner. Censoring in the survival analysis was performed if the event of interest (death of the patient) was not observed because of termination of the study observation period before the recruited subjects had shown the event of interest. These were 25 cases in the group of patients without TACE (25/33; 75.8%), and 42 cases (42/55; 76.4%) in the TACE group. Statistically significant values were assumed for p≤0.05.

Results
=======

[Table 1](#t1-anntransplant-25-e919414){ref-type="table"} provides a summary of the clinical background, underlying liver disease, and demographics of the patients included in the study. The underlying liver disease in 59/88 (67.0%) patients was alcoholic liver cirrhosis. NASH was diagnosed in 9/88 (10.2%) patients. Viral hepatitis was detected in 19/88 (21.6%) cases. Hemochromatosis was seen in 2/88 (2.2%) patients. Tumor recurrence with lethal complication proved to be the most common cause of death in the transplant patients. In patients receiving TACE, in 6/55 (10.9%) cases, local HCC recurrence in the graft was diagnosed. Graft HCC recurrence with concomitant metastatic spread was observed in 5/55 (9.0%) patients. Another 4/55 (7.2%) patients developed metastases to distant organs without evidence of local graft tumor recurrence. Altogether, 9/55 (16.4%) cases showed metastatic disease. In 13/55 (23.6%) cases, death occurred in the subsequent course. In 8/55 (14.5%) patients, the cause of death was HCC recurrence leading to lethal complications. In another 2/55 (3.6%) patients, graft failure due to recurrent viral hepatitis leading to complications of graft cirrhosis and liver failure were the main cause of death. Post-transplant gastric cancer with metastatic spread was the ultimate cause of death in 1/55 (1.8%) patients. A lethal Fournier's gangrene was documented in 1/55 (1.8%) patients. In 1 case, the cause of death remained unknown. In the group of patients without TACE, local HCC recurrence with metastatic spread was observed in 4/33 (12.1%) patients. Another 5/33 (15.1%) patients had local recurrence without distant metastases. In 8/33 (24.2%) cases, patient death was documented in the subsequent course. Recurrent HCC with lethal complications was the cause of death in 5/33 (15.1%) patients, and fulminant stroke was observed in 1/33 (3.0%) patients. In 2 cases the cause of death remained unknown.

Host hepatic factors of angiogenesis are associated with graft rejection and M2-polarized macrophages
-----------------------------------------------------------------------------------------------------

Clinicopathological characteristics of patients with and without neoadjuvant TACE are summarized in [Table 1](#t1-anntransplant-25-e919414){ref-type="table"}. As expected, patients undergoing TACE had smaller tumors (≤20 mm) and more advanced T stage prior to LTX, and had decreased incidence of distant metastasis and graft rejection after LTX. [Figure 2](#f2-anntransplant-25-e919414){ref-type="fig"} provides example photographs of angiopoietins and cellular immunologic infiltrates in the explanted host liver. [Tables 1](#t1-anntransplant-25-e919414){ref-type="table"}[](#t2-anntransplant-25-e919414){ref-type="table"}[](#t3-anntransplant-25-e919414){ref-type="table"}[](#t4-anntransplant-25-e919414){ref-type="table"}--[5](#t5-anntransplant-25-e919414){ref-type="table"} give a synopsis of the statistical evaluation of all patients.

The presence of angiopoietin-2 at the TIF in the explanted liver was associated with graft rejection after LTX (p=0.019; [Figure 2A, 2B](#f2-anntransplant-25-e919414){ref-type="fig"}; [Table 3](#t3-anntransplant-25-e919414){ref-type="table"}). In the Ang2^−^ group, only 1/8 (12.5%) patients had organ rejection, but in the Ang2^+^ group, 15/25 (25.0%) patients suffered organ rejection. In HCC patients who received TACE prior to LTX, the angiopoietins in the TCA or at TIF were associated with the presence of CD163^+^ TAMs ([Table 3](#t3-anntransplant-25-e919414){ref-type="table"}). In the Ang1^+^ group, 12/17 (70.6%) patients showed CD163^+^ TAMs at the TIF, but in the Ang1^−^ group only 14/38 (36.8%) patients showed CD163^+^ TAMs at the TIF (p=0.021).

Monocytes/macrophages are associated with tumor size, grading, angioinvasion, and metastatic disease
----------------------------------------------------------------------------------------------------

In patients without TACE, TEMs and CD68^+^ TAMs were associated with a larger tumor size ([Figure 2C--2F](#f2-anntransplant-25-e919414){ref-type="fig"}, [Table 4](#t4-anntransplant-25-e919414){ref-type="table"}). In the TEM^−^ group, 15/21 (71.4%) patients had a smaller tumor size, whereas in the TEM^+^ group only 4/12 (33.3%) patients had this feature (p=0.033). In addition, the presence of CD68^+^ TAMs in TCA revealed an identical phenomenon (p=0.033; [Table 4](#t4-anntransplant-25-e919414){ref-type="table"}). In the TIF, CD68^+^ TAMs were associated with more frequent angioinvasion (p=0.038). In the CD68^−^ group, angioinvasion was detected in 2/28 (7.1%) patients. This was also the case in 2/5 (40%) patients in the CD68^+^ group. Moreover, CD163^+^ TAMs in TIF were associated with a more frequent metastasis after LTX (p=0.038). In the CD163^−^ group, 2/28 (7.1%) patients had distant metastases, but in the CD163^+^ group 3/5 (60.0%) patients had distant metastases, when considering the TIF (p=0.038; [Table 4](#t4-anntransplant-25-e919414){ref-type="table"}).

In patients who received TACE prior to LTX, monocytes/macrophages were associated with a more advanced tumor grading ([Table 4](#t4-anntransplant-25-e919414){ref-type="table"}). In the CD68^+^ group, 8/10 (80.0%) patients had G2/G3 tumors. In the CD68^−^ group, only 18/45 (40.0%) patients revealed this characteristic (p=0.022). Interestingly, the presence of CD68^+^ TAMs and TEMs in these pre-treated tumors were strongly associated: in the CD68^+^ group 34/39 (87.2%) patients showed TEMs in the TCA, but in the CD68^−^ group 9/16 (56.3%) patients showed TEMs in the TCA (p=0.012).

Tumor necrosis is associated with angiopoietin expression, M2-polarized TAMs, and reduced incidence of tumor recurrence
-----------------------------------------------------------------------------------------------------------------------

24/33 (72.7%) patients without TACE showed no tumor necrosis in the HCC group ([Table 5](#t5-anntransplant-25-e919414){ref-type="table"}). High expression of angiopoietin-1 in tumor cells in the TIF was associated with tumor necrosis: in the Ang1^+^ group 8/9 (88.9%) of the HCC showed tumor necrosis, but in the Ang1^−^ group 11/24 (45.8%) of the HCC showed tumor necrosis (p=0.026).

In 46/55 (83.6%) of the patients with TACE prior to LTX, tumor necrosis was detected and was associated with enhanced infiltration of CD163^+^ TAMs (p=0.018; [Table 5](#t5-anntransplant-25-e919414){ref-type="table"}). In the Necrosis^+^ group 25/46 (54.3%) patients showed TEMs in the TCA, but in the Necrosis^−^ group only 1/9 (11.1%) patients showed TEMs in the TCA. Furthermore, tumor necrosis was associated with a lower incidence of recurrent graft HCC after TACE and LTX (p=0.018). In the Necrosis^+^ group only in 3/46 (6.5%) patients had tumor necrosis, but in the Necrosis^−^ group the tumor recurred in 3/9 (33.3%) patients.

Presence of monocytes/macrophages in the host liver is associated with survival after transplantation
-----------------------------------------------------------------------------------------------------

Recipient hepatic TEMs and CD68^+^ TAMs were associated with patient overall survival after LTX without TACE ([Figure 3](#f3-anntransplant-25-e919414){ref-type="fig"}, [Tables 1](#t1-anntransplant-25-e919414){ref-type="table"}[](#t2-anntransplant-25-e919414){ref-type="table"}[](#t3-anntransplant-25-e919414){ref-type="table"}[](#t4-anntransplant-25-e919414){ref-type="table"}--[5](#t5-anntransplant-25-e919414){ref-type="table"}). In the TCA, TEMs were associated with lower patient survival (p=0.026). At 1, 3, and 5 years after LTX, 70.8%, 56.8%, and 56.8%, respectively, of patients in the TEM^+^ group were alive, in comparison to 93.3%, 88.2%, and 88.2%, respectively, of patients in the TAM^−^ group ([Figure 3A](#f3-anntransplant-25-e919414){ref-type="fig"}). Furthermore, CD68^+^ TAMs in TCA were associated with worse patient survival (p=0.026; [figure 3B](#f3-anntransplant-25-e919414){ref-type="fig"}): At 1, 3, and 5 years after surgery, the overall survival was 63.8%, 42.6%, and 42.6%, respectively, in patients with, but it was 94.6%, 90.1%, and 90.1%, respectively, in patients without CD68^+^ TAMs at the TCA.

Discussion
==========

Our study assessed the relationship of presence of angiopoietin-positive tumor cells, infiltrating monocytes/macrophages, and tumor necrosis in HCC samples from the recipient liver prior to LTX with tumor recurrence, survival, and graft rejection. Nearly two-third of the patients were pre-treated with TACE. We hypothesized that, in the tumor microenvironment of HCC, monocytes/macrophages, angiopoietins, and tumor necrosis are coherently interconnected and can influence the outcome after oncologic LTX. The main findings were: (1) Monocytes/macrophages in the recipient native liver prior to LTX influence survival after transplantation; (2) when receiving TACE, development of tumor necrosis was associated with lower incidence of recurrent HCC following LTX and with enhanced expression of monocytes/macrophages and angiopoietin-2; (3) pre-transplant expression of angiopoietin-2 in tumor cells was associated to more frequent graft rejection after LTX; (4) monocytes/macrophages were associated with angioinvasion, tumor size, and metastatic disease.

HCC is the hallmark of inflammation-associated cancer. Tumor-related escape mechanisms such as inadequate tumor clearance and suppression of anti-tumor immunity are among the most challenging paradigms in hepatology \[[@b19-anntransplant-25-e919414]\]. In chronic hepatic inflammation, infiltrating monocytes/macrophages in the tumor microenvironment have long been recognized as essential drivers of tumor progression \[[@b20-anntransplant-25-e919414]\]. Cancer is related with major immunosuppression of the host, which is significantly aggravated after LTX. There is little data on the importance of host immunologic competence in the tumor microenvironment in clinical outcome following solid organ transplantation. Here, we demonstrated that host hepatic monocytes/macrophages, angiogenesis-related factors, and occurrence of post-interventional tumor necrosis are coherently related and exert a significant effect on patient outcome after LTX.

Our study demonstrated that high abundance of angiopoietin in the explanted recipient's liver was associated with graft rejection after oncologic LTX. Scientific data on the importance of angiopoietins in solid organ transplantation are scarce. However, recent data suggest there are functional links between angiopoietins and enhanced immunologic infiltration \[[@b21-anntransplant-25-e919414]\]. In the present study of oncologic LTX, angiopoietin expression was found to be associated with increased infiltration of monocytes/macrophages. Thus, elevated expression of recipient's factors of angiogenesis can facilitate enhanced infiltration of the graft with immune-competent and antigen-presenting cells after transplantation. This phenomenon can trigger immunologic mechanisms that ultimately lead to increased incidence of organ rejection. These findings suggest that angiopoietin signaling influences infiltration of monocytes/macrophages in HCC, leading to worse disease outcomes; however, additional research is warranted to elucidate the mechanistic links.

In the context of hepatocarcinogenesis, HCC-associated monocyte/macrophage subsets are novel targets of immunologic checkpoint inhibition, and *in vivo* targeting of myeloid cell populations that control crucial hepatic inflammatory responses might be new approaches for efficient drug delivery \[[@b22-anntransplant-25-e919414]\]. In addition, manipulating the role of CD68-positive Kupffer cells in regulating the initial hepatic injury, aggravating the immunologic cascades by infiltrating monocytes, and their consequent re-/programming into tumor-promoting M2-polarized phenotypes, are promising targets for novel therapeutic interventions. In our study, we demonstrated that TEMs and CD68^+^ macrophages are significantly associated with multiple tumor characteristics and worse survival after LTX. Of note, the experimental depletion of Kupffer cells *in vivo* was demonstrated to attenuate hepatocarcinogenesis via cytokeratin 19/Oval-dependent pathways, which was related to improved response to treatment with sorafenib in this subgroup of patients \[[@b23-anntransplant-25-e919414]\]. TEMs were shown to indicate the effect of sorafenib therapy and to serve as a complementary biomarker for α-fetoprotein in diagnosing α-fetoprotein-negative advanced HCC \[[@b24-anntransplant-25-e919414],[@b25-anntransplant-25-e919414]\]. Furthermore, TEMs were demonstrated to directly respond to angiopoietin activity \[[@b26-anntransplant-25-e919414]\]. In experimental cancer models, selective depletion of TEMs and corresponding angiopoietin-related pathways significantly impaired tumor growth and angiogenesis \[[@b27-anntransplant-25-e919414]\].

Recent data indicate that the occurrence of histologic tumor necrosis is functionally mediated by infiltrating monocytes/macrophages \[[@b28-anntransplant-25-e919414]--[@b30-anntransplant-25-e919414]\]. Moreover, the utilization of bridging therapy such as TACE prior to LTX is associated with the extent of tumor necrosis of the recipient liver and supports the essential role of chemotherapy-induced cytotoxicity in TACE effectiveness \[[@b31-anntransplant-25-e919414]\]. We found that formation of host histologic tumor necrosis after TACE was associated with enhanced presence of monocytes/macrophages and reduced incidence of recurrent HCC after LTX. In this scenario, infiltrating TAMs and tumor necrosis represent important integrational components of a common phenomenon in tumor-related hepatic inflammation. In the oncologic setting, this construct comprising monocytes/macrophages and tumor necrosis may help to identify a patient subgroup with favorable characteristics and to predict their outcome after TACE and LTX.

Previous results published by our group revealed an important role of various components of the tumor microenvironment, such as infiltrating subsets of monocytes/macrophages, angiogenic biomarkers, and formation of necrosis in regard to tumor progression. Based on these findings, in the current work we hypothesized that in HCC prior transplantation, monocytes/macrophages and related factors of angiogenesis exert a significant effect on clinical outcome after LTX. We conceived a possible functional link, in which angiopoietins released by malignant cells and endothelium on tumor blood vessels mediate homing of monocytes/macrophages to the tumor microenvironment of HCC via the TIE2 receptors. Invading monocytes/macrophages then orchestrate the formation of histologic tumor necrosis, promote tumor escape mechanisms, and ultimately cause cancer progression ([Figure 4](#f4-anntransplant-25-e919414){ref-type="fig"}). Interestingly, in our study, these immunologic characteristics in the recipient native liver prior transplantation (i.e., the surgical removal of the HCC and related tumor microenvironment) were associated with the outcome after transplantation. However, this study has certain limitations. The relatively small study cohort and corresponding number of cases in the various subgroups are a major drawback. We demonstrated strong statistical associations, but the nature of our work remains descriptive. Thus, experimental mechanistic and functional downstream research will help clarify the causal pathways presumed in the present work.

Conclusions
===========

In the context of altered recipient immunologic competence after solid organ transplantation, there is scant data on the role of the angiopoietin axis, tumor necrosis, and monocytes/macrophages. Our study demonstrated a coherent pre-transplant construct composed of recipient hepatic angiogenic factors, monocytes/macrophages, and tumor necrosis associated with numerous clinicopathologic variables and disease outcome after LTX for HCC. However, possible limitations should be taken into consideration, as well. The small number of cases with liver transplantation on grounds of underlying HCC represent the main obstacle. The descriptive nature of our findings may also be of potential limitation. Thus, further research is warranted to elucidate the possible functional links, which could help identify novel targets of immunologic checkpoint inhibition in liver cancer.
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![Flowchart depicting the patient selection process for our study.](anntransplant-25-e919414-g001){#f1-anntransplant-25-e919414}

![Immunohistology for cellular infiltrates and angiopoietins in the host tumor central area (TCA) prior to liver transplantation for HCC (LTX) (left/right column: images of a typical patient/group with/without the respective positive staining are shown). The arrows point to positive staining; microvessels are indicated by asterisks; scale bar 50 μm. (**A**) High angiopoietin-1 frequency. (**B**) Low angiopoietin-1 frequency. (**C**) High frequency of TEMs. (**D**) Low frequency of TEMs. (**E**) High frequency of CD68^+^ TAMs. (**F**) Low frequency of CD68^+^ monocytes/macrophages. (**G**) High frequency of CD163^+^ monocytes/macrophages. (**H**) Low frequency of CD163^+^ monocytes/macrophages.](anntransplant-25-e919414-g002){#f2-anntransplant-25-e919414}

![(**A**) Overall survival after LTX in relation to occurrence of host hepatic TEMs. (**B**) Overall survival after LTX in relation to occurrence of host hepatic CD68^+^ monocytes/macrophages.](anntransplant-25-e919414-g003){#f3-anntransplant-25-e919414}

![We hypothesized that angiopoietin-related molecular links mediate homing of TEMs to the microenvironment of HCC utilizing the TIE2-axis. These tumor-infiltrating monocytes/macrophages are then responsible for the establishment of necrosis, further tumor escape mechanisms, and cancer growth.](anntransplant-25-e919414-g004){#f4-anntransplant-25-e919414}

###### 

Clinicopathological characteristics of patients undergoing liver transplantation for hepatocellular carcinoma.

  Variable                      Without TACE (n=33)   With TACE (n=55)   p
  ----------------------------- --------------------- ------------------ -----------
  Patient age (years)                                                    
   ≤60                          14 (42.4)             23 (41.8)          0.956
   \>60                         19 (57.6)             32 (58.2)          
  Gender                                                                 
   Male                         26 (78.8)             47 (85.5)          0.421
   Female                       7 (21.2)              8 (14.5)           
  Graft tumour recurrence                                                
   With                         5 (15.2)              6 (10.9)           0.560
   Without                      28 (84.8)             49 (89.1)          
  Distant metastases                                                     
   With                         4 (12.1)              9 (16.4)           **0.007**
   Without                      29 (87.9)             46 (83.6)          
  Graft rejection                                                        
   With                         16 (48.5)             13 (23.6)          **0.016**
  6Without                      17 (51.5)             42 (76.4)          
  Tumour size (mm)                                                       
   ≤20                          19 (57.6)             44 (80.0)          **0.030**
   \>20                         14 (42.4)             11 (20.0)          
  Angioinvasion                                                          
   Positive                     4 (12.1)              6 (10.9)           0.862
  Negative                      29 (87.9)             49 (89.1)          
  Lymphangiosis carcinomatosa                                            
   Positive                     1 (3.0)               7 (12.7)           0.126
   Negative                     32 (97.0)             48 (87.3)          
  Histologic differentiation                                             
   G1 well                      15 (45.5)             29 (52.7)          0.509
   G2 moderate/G3 poor          18 (54.5)             26 (47.3)          
  Pathologic T stage                                                     
   T1                           28 (84.8)             27 (49.1)          **0.001**
   T2/T3                        5 (15.2)              28 (50.9)          
  Alcoholic liver cirrhosis                                              
   With                         19 (57.6)             40 (72.7)          0.143
   Without                      14 (42.4)             15 (27.3)          
  Viral hepatitis                                                        
   With                         10 (30.3)             9 (16.4)           0.124
   Without                      23 (69.7)             46 (83.6)          
  NASH                                                                   
   With                         2 (6.1)               7 (12.7)           0.318
   Without                      31 (93.9)             48 (87.3)          
  Hemochromatosis                                                        
   With                         2 (6.1)               0 (0.0)            0.065
   Without                      31 (93.9)             55 (100.0)         

###### 

Group assignment of the patients undergoing liver transplantation for hepatocellular carcinoma in our study.

  Assessment of        Tumour area   TACE      Positive/presence   Negative/absence
  -------------------- ------------- --------- ------------------- ------------------
  Ang-2                TIF           Without   ANG2^+^ *n*=25      ANG2^−^ *n*=8
  Ang-2                TIF           With      ANG2^+^ *n*=38      ANG2^−^ *n*=17
  Ang-1                TIF           Without   ANG1^+^ *n*=19      ANG1^−^ *n*=14
  Ang-1                TIF           With      ANG1^+^ *n*=17      ANG1^−^ *n*=38
  TEMs                 TCA           Without   TEM^+^ *n*=12       TEM^−^ *n*=21
  TEMs                 TCA           With      TEM^+^ *n*=12       TEM^−^ *n*=43
  CD68^+^ TAMs         TCA           Without   CD68^+^ *n*=12      CD68^−^ *n*=21
  CD68^+^ TAMs         TCA           With      CD68^+^ *n*=16      CD68^−^ *n*=39
  M2-polaryzed TAMs    TIF           Without   CD163^+^ *n*=28     CD163^−^ *n*=5
  M2-polaryzaed TAMs   TIF           With      CD163^+^ *n*=6      CD163^−^ *n*=49

Ang-2 -- angiopoetin-2; Ang-1 -- angiopoetin-1; TAM -- tumor associated macrophage; TCA -- tumor central area; TEM -- Tie2-expressing monocyte; TIF -- tumor infiltrating front.

###### 

Correlation of host hepatic angiopoietin-1 expression at the tumour-infiltrating front (TIF) or central area (TCA) with clinicopathological characteristics of the patients undergoing liver transplantation for hepatocellular carcinoma.

  Variable                      Without TACE   With TACE                                            
  ----------------------------- -------------- ------------- ------------ ------------ ------------ -------
  No. of patients               25             8                          38           17           
  Age                                                                                               
   ≤60                          12 (52.6%)     2 (25.0%)     0.252        17 (44.7%)   6 (35.3%)    0.512
   \<60                         13 (47.4%)     6 (75.0%)     21 (55.3%)   11 (64.7%)                
  Gender                                                                                            
   Male                         19 (76.0%)     7 (87.5%)     0.489        31 (81.6%)   16 (94.1%)   0.223
   Female                       6 (24.0%)      1 (12.5%)     7 (18.4%)    1 (5.9%)                  
  Graft tumour recurrence                                                                           
   Positive                     2 (10.5%)      3 (21.4%)     0.388        3 (17.6%)    3 (13.2%)    0.284
   Negative                     17 (89.5%)     11 (78.6%)    35 (82.4%)   14 (82.4%)                
  Distant metastases                                                                                
   Positive                     3 (12.0%)      1 (12.5%)     0.970        6 (15.8%)    3 (17.6%)    0.863
   Negative                     22 (88.0%)     7 (87.5%)     32 (84.2%)   14 (82.4%)                
  Graft rejection                                                                                   
   With                         15 (60.0%)     1 (12.5%)     **0.019**    9 (23.7%)    4 (23.5%)    0.990
   Without                      10 (40.0%)     7 (87.5%)     29 (76.7%)   13 (76.5%)                
  Tumour size, mm                                                                                   
   ≤20                          15 (60.0%)     611 (22.4%)   0.618        30 (78.9%)   14 (82.4%)   0.770
   \>20                         10 (40.0%)     638 (77.6%)   8 (21.1%)    3 (17.6%)                 
  Angioinvasion                                                                                     
   Positive                     3 (12.0%)      1 (12.5%)     0.970        3 (7.9%)     3 (17.6%)    0.284
   Negative                     22 (88.0%)     67 (87.5%)    35 (92.1%)   14 (82.4%)                
  Lymphangiosis carcinomatosa                                                                       
   Positive                     1 (4.0%)       0 (0.0%)      0.566        4 (10.5%)    3 (17.6%)    0.464
   Negative                     24 (96.0%)     68 (100.0%)   34 (89.5%)   14 (82.4%)                
  Histologic differentiation                                                                        
   G1 well                      5 (20.0%)      1 (12.5%)     0.632        21 (55.3%)   8 (47.1%)    0.573
   G2 moderate/G3 poor          20 (80.0%)     7 (87.5%)     17 (44.7%)   9 (52.9%)                 
  Pathologic T stage                                                                                
   T1                           21 (84.0%)     7 (87.5%)     0.810        18 (47.4%)   9 (52.9%)    0.702
   T2/T3                        4 (16.0%)      1 (12.5%)     20 (52.6%)   8 (47.1%)                 

  Variable                      Without TACE   With TACE                                             
  ----------------------------- -------------- ------------ ------------- ------------- ------------ -----------
  No. of patients               19             14                         17            38           
  Age                                                                                                
   ≤60                          10 (52.6%)     4 (28.6%)    0.167         8 (47.1%)     15 (39.5%)   0.598
   \<60                         9 (47.4%)      10 (71.4%)   9 (52.9%)     623 (60.5%)                
  Gender                                                                                             
   Male                         13 (68.4%)     13 (92.9%)   0.09          15 (88.2%)    32 (84.2%)   0.696
   Female                       6 (31.6%)      1 (7.1%)     2 (11.8%)     6 (15.8%)                  
  Graft tumour recurrence                                                                            
   Positive                     2 (10.5%)      3 (21.4%)    0.388         1 (5.9%)      5 (13.2%)    0.424
   Negative                     17 (89.5%)     11 (78.6%)   616 (94.1%)   33 (86.8%)                 
  Distant metastases                                                                                 
   Positive                     2 (10.5%)      2 (14.3%)    0.744         2 (11.8%)     7 (18.4%)    0.537
   Negative                     17 (89.5%)     12 (85.7%)   15 (88.2%)    31 (81.6%)                 
  Graft rejection                                                                                    
   With                         10 (52.6%)     6 (42.9%)    0.579         3 (17.6%)     10 (26.3%)   0.484
   Without                      9 (47.4%)      8 (57.1%)    14 (82.4%)    28 (73.7%)                 
  Tumour size, mm                                                                                    
   ≤20                          9 (47.4%)      10 (71.6%)   0.167         2 (11.8%)     29 (76.3%)   0.307
   \>20                         10 (52.6%)     4 (28.6%)    615 (88.2%)   9 (23.7%)                  
  Angioinvasion                                                                                      
   Positive                     3 (15.8%)      1 (7.1%)     0.452         3 (17.6%)     3 (7.9%)     0.284
   Negative                     16 (84.2%)     13 (92.9%)   614 (82.4%)   35 (92.1%)                 
  Lymphangiosis carcinomatosa                                                                        
   Positive                     0 (0.0%)       1 (7.1%)     0.237         2 (11.8%)     5 (13.2%)    0.886
   Negative                     19 (100.0%)    13 (92.9%)   615 (88.2%)   33 (86.8%)                 
  Histologic differentiation                                                                         
   G1 well                      9 (47.4%)      6 (42.9%)    0.797         8 (47.1%)     21 (55.3%)   0.573
   G2 moderate/G3 poor          10 (52.6%)     8 (57.1%)    9 (52.9%)     17 (44.7%)                 
  Pathologic T stage                                                                                 
   T1                           15 (78.9%)     13 (92.9%)   0.271         8 (47.1%)     19 (50.0%)   0.840
   T2/T3                        4 (21.1%)      1 (7.1%)     9 (52.9%)     19 (50.0%)                 
  CD163^+^ TAMs in TCA                                                                               
   Positive                     9 (47.4%)      10 (71.6%)   0.167         5 (29.4%)     24 (63.2%)   **0.021**
   Negative                     10 (52.6%)     4 (28.6%)    12 (70.6%)    14 (36.8%)                 

###### 

Correlation of host hepatic monocytes/macrophages subtypes at the tumour-central area (TCA) or tumour infiltrating front (TIF) with clinicopathological characteristics of patients undergoing liver transplantation for hepatocellular carcinoma.

  Variable                      Without TACE   With TACE                                            
  ----------------------------- -------------- ------------- ------------ ------------ ------------ -------
  No. of patients               12             21                         12           43           
  Age                                                                                               
   ≤60                          5 (41.7%)      9 (42.9%)     0.947        2 (16.7%)    21 (48.8%)   0.395
   \<60                         7 (58.3%)      12 (57.1%)    10 (83.3%)   22 (51.2%)                
  Gender                                                                                            
   Male                         8 (66.7%)      18 (85.7%)    0.198        9 (75.0%)    38 (88.4%)   0.245
   Female                       4 (33.3%)      63 (14.3%)    3 (25.0%)    5 (11.6%)                 
  Graft tumour recurrence                                                                           
   Positive                     2 (16.7%)      3 (14.3%)     0.854        1 (8.3%)     5 (11.6%)    0.746
   Negative                     10 (83.3%)     18 (85.7%)    11 (91.7%)   38 (88.4%)                
  Distant metastases                                                                                
   Positive                     2 (16.7%)      2 (9.5%)      0.545        3 (25.0%)    6 (14.0%)    0.360
   Negative                     10 (83.3%)     19 (90.5%)    9 (75.0%)    37 (86.0%)                
  Graft rejection                                                                                   
   With                         4 (33.3%)      12 (57.1%)    0.188        2 (16.7%)    11 (25.6%)   0.520
   Without                      8 (66.7%)      9 (42.9%)     10 (83.3%)   32 (74.4%)                
  Tumour size, mm                                                                                   
   ≤20                          4 (33.3%)      15 (71.4%)    **0.033**    8 (66.7%)    36 (83.7%)   0.192
   \>20                         8 (66.7%)      6 (28.6%)     4 (33.3%)    7 (16.3%)                 
  Angioinvasion                                                                                     
   Positive                     2 (16.7%)      2 (9.5%)      0.545        2 (16.7%)    4 (9.3%)     0.469
   Negative                     10 (83.3%)     619 (90.5%)   10 (83.3%)   39 (90.7%)                
  Lymphangiosis carcinomatosa                                                                       
   Positive                     0 (0.0%)       1 (4.8%)      0.443        3 (25.0%)    4 (9.3%)     0.149
   Negative                     12 (100.0%)    20 (95.2%)    9 (75.0%)    39 (90.7%)                
  Histologic differentiation                                                                        
   G1 well                      5 (41.7%)      10 (47.6%)    0.741        6 (50.0%)    23 (53.5%)   0.831
   G2 moderate/G3 poor          7 (58.3%)      11 (52.4%)    6 (50.0%)    20 (46.5%)                
  Pathologic T stage                                                                                
   T1                           10 (83.3%)     18 (85.7%)    0.854        6 (50.0%)    21 (48.8%)   0.943
   T2/T3                        2 (16.7%)      3 (14.3%)     6 (50.0%)    22 (51.2%)                

  Variable                      Without TACE   With TACE                                              
  ----------------------------- -------------- ------------ ------------- ------------- ------------- -----------
  No. of patients               12             21                         16            39            
  Gender                                                                                              
   ≤60                          5 (41.7%)      9 (42.9%)    0.947         3 (18.8%)     20 (51.3%)    0.026
   \<60                         7 (58.3%)      12 (57.1%)   13 (81.3%)    19 (48.7%)                  
  Gender                                                                                              
   Male                         9 (75.0%)      17 (81.0%)   0.687         13 (81.3%)    34 (87.2%)    0.571
   Female                       3 (25.0%)      4 (19.0%)    3 (18.8%)     5 (12.8%)                   
  Graft tumour recurrence                                                                             
   Positive                     3 (25.0%)      2 (9.5%)     0.854         1 (6.3%)      5 (12.8%)     0.478
   Negative                     9 (75.0%)      19 (90.5%)   15 (93.8%)    34 (87.2%)                  
  Distant metastases                                                                                  
   Positive                     2 (16.7%)      2 (9.5%)     0.545         1 (6.3%)      8 (20.5%)     0.194
   Negative                     10 (83.3%)     19 (90.5%)   15 (93.8%)    31 (79.5%)                  
  Graft rejection                                                                                     
   With                         6 (50.0%)      10 (47.6%)   0.895         3 (18.8%)     611 (25.6%)   0.585
   Without                      6 (50.0%)      11 (52.4%)   13 (81.3%)    32 (74.4%)                  
  Tumour size, mm                                                                                     
   ≤20                          4 (33.3%)      15 (71.4%)   **0.033**     15 (93.8%)    29 (74.4%)    0.102
   \>20                         8 (66.7%)      6 (28.6%)    1 (6.3%)      10 (25.6%)                  
  Angioinvasion                                                                                       
   Positive                     1 (8.3%)       3 (14.3%)    0.545         2 (12.5%)     4 (10.3%)     0.808
   Negative                     11 (91.7%)     18 (85.7%)   14 (87.5%)    35 (89.7%)                  
  Lymphangiosis carcinomatosa                                                                         
   Positive                     0 (0.0%)       1 (4.8%)     0.443         0 (0.0%)      7 (17.9%)     0.070
   Negative                     12 (100.0%)    20 (95.2%)   16 (100.0%)   632 (82.1%)                 
  Histologic differentiation                                                                          
   G1 well                      8 (66.7%)      7 (33.3%)    0.064         9 (56.3%)     20 (53.5%)    0.737
   6G2 moderate/G3 poor         4 (33.3%)      14 (66.7%)   7 (43.8%)     619 (48.7%)                 
  Pathologic T stage                                                                                  
   T1                           18 (85.7%)     10 (83.3%)   0.854         12 (75.0%)    15 (38.5%)    0.014
   T2/T3                        3 (14.3%)      2 (16.7%)    4 (25.0%)     24 (61.5%)                  
  TEMs in TCA                                                                                         
   Positive                     13 (61.9%)     8 (66.7%)    0.544         34 (87.2%)    9 (56.3%)     **0.012**
   Negative                     8 (38.1%)      4 (33.3%)    5 (12.8%)     7 (43.8%)                   
  No. of patients               5              28                         45            10            
  Angioinvasion                                                                                       
   Positive                     2 (40.0%)      2 (7.1%)     **0.038**     4 (8.9%)      2 (20.0%)     0.308
   Negative                     3 (60.0%)      26 (92.9%)   41 (91.1%)    68 (80.0%)                  
  Histologic differentiation                                                                          
   G1 well                      2 (40.0%)      13 (46.4%)   0.790         27 (60.0%)    2 (20.0%)     **0.022**
   G2 moderate/G3 poor          3 (60.0%)      15 (53.6%)   18 (40.0%)    8 (80.0%)                   

  Variable             Without TACE   With TACE                                         
  -------------------- -------------- ----------- ------------ ------------ ----------- -------
  No. of patients      28             5                        6            49          
  Distant metastases                                                                    
   Positive            2 (7.1%)       2 (40.0%)   **0.038**    0 (00.0%)    9 (18.4%)   0.251
   Negative            26 (92.9%)     3 (60.0%)   6 (100.0%)   40 (81.6%)               

###### 

Correlation of host hepatic tumour necrosis with clinicopathological characteristics of the patients undergoing liver transplantation for hepatocellular carcinoma.

  Variable                      Without TACE   With TACE                                           
  ----------------------------- -------------- ------------ ------------ ------------ ------------ -----------
  No. of patients                              9            24           46           9            
  Age                                                                                              
   ≤60                          5 (55.6%)      9 (37.5%)    0.350        21 (45.7%)   2 (22.2%)    0.193
   \<60                         4 (44.4%)      15 (62.5%)   25 (54.3%)   7 (77.8%)                 
  Gender                                                                                           
   Male                         7 (77.8%)      19 (79.2%)   0.931        39 (84.8%)   8 (88.9%)    0.749
   Female                       2 (22.2%)      5 (20.8%)    7 (15.2%)    1 (11.1%)                 
  Graft tumour recurrence                                                                          
   Positive                     2 (22.2%)      3 (12.5%)    0.488        3 (6.5%)     3 (33.3%)    **0.018**
   Negative                     7 (77.8%)      21 (87.5%)   43 (93.5%)   6 (66.7%)                 
  Distant metastases                                                                               
   Positive                     2 (22.2%)      2 (8.3%)     0.276        6 (13.0%)    3 (33.3%)    0.132
   6Negative                    7 (77.8%)      22 (91.7%)   40 (87.0%)   6 (66.7%)                 
  Graft rejection                                                                                  
   With                         4 (44.4%)      12 (50.0%)   0.776        12 (26.1%)   1 (11.1%)    0.333
   Without                      5 (55.6%)      12 (50.0%)   34 (73.9%)   8 (88.9%)                 
  Tumour size, mm                                                                                  
   ≤20                          3 (33.3%)      16 (66.7%)   0.084        35 (76.1%)   9 (100.0%)   0.101
   \>20                         6 (66.7%)      8 (33.3%)    11 (23.9%)   0 (00.0%)                 
  Angioinvasion                                                                                    
   Positive                     2 (22.2%)      2 (8.3%)     0.276        6 (13.0%)    0 (00.0%)    0.251
   Negative                     7 (77.8%)      22 (91.7%)   40 (87.0%)   9 (100.0%)                
  Lymphangiosis carcinomatosa                                                                      
   Positive                     0 (0.0%)       1 (4.2%)     0.534        6 (13.0%)    1 (11.1%)    0.874
   Negative                     9 (100.0%)     23 (95.8%)   40 (87.0%)   8 (88.9%)                 
  Histologic differentiation                                                                       
   G1 well                      3 (33.3%)      12 (50.0%)   0.392        25 (54.3%)   4 (44.4%)    0.586
   G2 moderate/G3 poor          6 (66.7%)      12 (50.0%)   21 (45.7%)   5 (55.6%)                 
  Pathologic T stage                                                                               
   T1                           6 (66.7%)      22 (91.7%)   0.074        26 (56.5%)   1 (11.1%)    **0.013**
   T2/T3                        3 (33.3%)      2 (8.3%)     20 (43.5%)   8 (88.9%)                 
  CD163^+^ TAMs in TCA                                                                             
   Positive                     4 (44.4%)      15 (62.5%)   0.350        21 (45.7%)   8 (88.9%)    **0.018**
   Negative                     5 (55.6%)      9 (37.5%)    25 (54.3%)   1 (11.1%)                 
  Angiopoietin-1/TIF                                                                               
   Positive                     8 (88.9%)      11 (45.8%)   **0.026**    31 (67.4%)   7 (77.8%)    0.537
   Negative                     1 (11.1%)      13 (54.2%)   15 (32.6%)   2 (22.2%)                 
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